Advances in Thymidine Kinase 2 Deficiency: Clinical Aspects, Translational Progress, and Emerging Therapies
Authors:
Open Access
- 1 March 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 9 (2) , 225-235
Abstract
Defects in the replication, maintenance, and repair of mitochondrial DNA (mtDNA) constitute a growing and genetically heterogeneous group of mitochondrial disorders. Multiple genes participate in these processes, including thymidine kinase 2 (TK2) encoding the mitochondrial matrix protein TK2, a critical component of the mitochondrial nucleotide salvage pathway. TK2 deficiency (TK2d) causes mtDNA depletion, multiple deletions, or both, which manifest predominantly as mitochondrial myopathy. A wide clinical spectrum phenotype includes a severe, rapidly progressive, early onset form (median survival: < 2 years); a less severe childhood-onset form; and a late-onset form with a variably slower rate of progression. Clinical presentation typically includes progressive weakness of limb, neck, facial, oropharyngeal, and respiratory muscle, whereas limb myopathy with ptosis, ophthalmoparesis, and respiratory involvement is more common in the late-onset form. Deoxynucleoside monophosphates and deoxynucleosides that can bypass the TK2 enzyme defect have been assessed in a mouse model, as well as under open-label compassionate use (expanded access) in TK2d patients, indicating clinical efficacy with a favorable side-effect profile. This treatment is currently undergoing testing in clinical trials intended to support approval in the US and European Union (EU). In the early expanded access program, growth differentiation factor 15 (GDF-15) appears to be a useful biomarker that correlates with therapeutic response. With the advent of a specific treatment and given the high morbidity and mortality associated with TK2d, clinicians need to know how to recognize and diagnose this disorder. Here, we summarize translational research about this rare condition emphasizing clinical aspects.Keywords
This publication has 52 references indexed in Scilit:
- Onset and organ specificity of Tk2 deficiency depends on Tk1 down-regulation and transcriptional compensationHuman Molecular Genetics, 2010
- Enzymatic Regulation of Cytosolic Thymidine Kinase 1 and Mitochondrial Thymidine Kinase 2: A Mini ReviewNucleosides, Nucleotides & Nucleic Acids, 2010
- Genetic causes of mitochondrial DNA depletion in humansBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndromeBrain, 2008
- Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenanceHuman Molecular Genetics, 2008
- Progressive loss of mitochondrial DNA in thymidine kinase 2-deficient miceHuman Molecular Genetics, 2008
- Mutant POLG2 Disrupts DNA Polymerase γ Subunits and Causes Progressive External OphthalmoplegiaThe American Journal of Human Genetics, 2006
- Mutation analysis in 16 patients with mtDNA depletionHuman Mutation, 2003
- Mitochondrial myopathy simulating spinal muscular atrophyPediatric Neurology, 1996
- Mitochondrial DNA depletion: Prevalence in a pediatric population referred for neurologic evaluationPediatric Neurology, 1996